CLINICAL_TRIALS
trial_result
· 2018-03-20
Clinical Trial Update: A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis [Phase 3]
Summary
Phase 3 trial evaluating certolizumab pegol as add-on therapy in Chinese patients with active rheumatoid arthritis; results posted March 20, 2018.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: UCB Pharma SA, Belgium | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2018-03-20